CANbridge Pharmaceuticals and GC Pharma Announce Greater China Licensing Agreement for Hunterase™ for Hunter Syndrome

BEIJING & SHANGHAI–(BUSINESS WIRE)–CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, and GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), announced an exclusive licensing agreement in the greater China area to commercialize Hunterase™, a human recombinant iduronate-2-sulfatase (IDS) enzyme replacement therapy for the treatment of Hunter syndrome. Developed by GC Pharma, Hunterase is marketed in more than ten countries worldwide. There is no approved treatment for Hunter syndrome in China, unlike in some parts of the world.

 

Read the full article by CANbridge Pharmaceuticals Inc., and GC Pharma